Pulse Biosciences (PLSE) is drawing fresh attention after reporting favorable safety and efficacy data from a European feasibility study of its nPulse Cardiac Catheter System and beginning enrollment in a U.S. pivotal atrial fibrillation trial.

At the latest share price of $19.61, Pulse Biosciences shows a 46.45% year to date share price return and a 157.69% three year total shareholder return, which indicates long term momentum despite recent short term share price weakness around clinical and earnings updates.

If this kind of medical technology story interests you, it may be worth scanning for other healthcare stocks using advanced AI, starting with the 35 healthcare AI stocks

With strong clinical headlines, a Zacks Rank upgrade and a share price sitting below the US$30 analyst target, investors may be wondering whether Pulse Biosciences is still underappreciated or whether the market is already pricing in future growth.

Most Popular Narrative: 10.9% Undervalued

The current $19.61 share price sits below the $22 narrative fair value, which frames Pulse Biosciences as a high growth, high expectation medical device stock.

Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.

Want to see what sits behind that confident growth story? The narrative leans on rapid revenue expansion, margin uplift, and a future earnings multiple that assumes real traction ahead.

Result: Fair Value of $22 (UNDERVALUED)

However, the story could change if trial results fail to clearly beat existing treatments, or if high costs and limited revenue keep losses heavy for longer.

Another angle on value

That 10.9% “undervalued” fair value of $22 sits awkwardly against one simple reality: Pulse Biosciences is loss making, generates $751,000 of revenue and the SWS DCF model suggests a future cash flow value of only $2.98 per share, well below the current $19.61 price. Which version of the story do you trust more?

Next Steps

Given the mixed signals in this story, it makes sense to look past the headlines and into the details yourself. Move quickly, weigh the clinical, valuation and financial trade offs, and ground your view in the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

Do not stop at a single stock story when there are structured ways to surface fresh ideas that fit different investing styles and risk levels.

• Target potential mispricing by scanning companies that combine quality and attractive pricing through the 51 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks with stronger financial foundations using the solid balance sheet and fundamentals stocks screener (44 results).
• Spot early opportunities by tracking smaller companies with room to grow via the 25 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.